DDInter923 DDInter922
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.[A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies.[A214280, A214295] On January 16, 2024, Iinebilizumab also received Health Canada approval for the same indication.
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a
Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Infliximab may lead to a major life threatening interaction when taken with Aldesleukin